233 related articles for article (PubMed ID: 26552829)
41. Peptide-Aptamer Coassembly Nanocarrier for Cancer Therapy.
Ma Y; Li W; Zhou Z; Qin X; Wang D; Gao Y; Yu Z; Yin F; Li Z
Bioconjug Chem; 2019 Mar; 30(3):536-540. PubMed ID: 30702869
[TBL] [Abstract][Full Text] [Related]
42. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization.
Cun D; Jensen DK; Maltesen MJ; Bunker M; Whiteside P; Scurr D; Foged C; Nielsen HM
Eur J Pharm Biopharm; 2011 Jan; 77(1):26-35. PubMed ID: 21093589
[TBL] [Abstract][Full Text] [Related]
43. Effective siRNA delivery to inflamed primary vascular endothelial cells by anti-E-selectin and anti-VCAM-1 PEGylated SAINT-based lipoplexes.
Leus NG; Talman EG; Ramana P; Kowalski PS; Woudenberg-Vrenken TE; Ruiters MH; Molema G; Kamps JA
Int J Pharm; 2014 Jan; 459(1-2):40-50. PubMed ID: 24239833
[TBL] [Abstract][Full Text] [Related]
44. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.
Heyes J; Palmer L; Bremner K; MacLachlan I
J Control Release; 2005 Oct; 107(2):276-87. PubMed ID: 16054724
[TBL] [Abstract][Full Text] [Related]
45. Cell Type-Specific Delivery of RNAi by Ligand-Functionalized Curdlan Nanoparticles: Balancing the Receptor Mediation and the Charge Motivation.
Wu Y; Cai J; Han J; Baigude H
ACS Appl Mater Interfaces; 2015 Sep; 7(38):21521-8. PubMed ID: 26345600
[TBL] [Abstract][Full Text] [Related]
46. Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy.
Aaldering LJ; Tayeb H; Krishnan S; Fletcher S; Wilton SD; Veedu RN
RNA Biol; 2015; 12(4):412-25. PubMed ID: 25849197
[TBL] [Abstract][Full Text] [Related]
47. Absolute quantification of cell-bound DNA aptamers during SELEX.
Avci-Adali M; Wilhelm N; Perle N; Stoll H; Schlensak C; Wendel HP
Nucleic Acid Ther; 2013 Apr; 23(2):125-30. PubMed ID: 23405949
[TBL] [Abstract][Full Text] [Related]
48. Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement.
Yan AC; Levy M
Nucleic Acid Ther; 2018 Jun; 28(3):194-199. PubMed ID: 29883295
[TBL] [Abstract][Full Text] [Related]
49. Monodispersed brush-like conjugated polyelectrolyte nanoparticles with efficient and visualized siRNA delivery for gene silencing.
Jiang R; Lu X; Yang M; Deng W; Fan Q; Huang W
Biomacromolecules; 2013 Oct; 14(10):3643-52. PubMed ID: 24040909
[TBL] [Abstract][Full Text] [Related]
50. A novel local anti-colorectal cancer drug delivery system: negative lipidoid nanoparticles with a passive target via a size-dependent pattern.
Ding W; Wang F; Zhang J; Guo Y; Ju S; Wang H
Nanotechnology; 2013 Sep; 24(37):375101. PubMed ID: 23965897
[TBL] [Abstract][Full Text] [Related]
51. Aptamer-targeted RNAi for HIV-1 therapy.
Zhou J; Rossi JJ
Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
[TBL] [Abstract][Full Text] [Related]
52. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.
Zhu H; Li J; Zhang XB; Ye M; Tan W
ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749
[TBL] [Abstract][Full Text] [Related]
53. What are the key targeted delivery technologies of siRNA now?
Sioud M
Methods Mol Biol; 2010; 629():93-107. PubMed ID: 20387145
[TBL] [Abstract][Full Text] [Related]
54. Non-viral Delivery Systems for Breast Cancer Gene Therapy.
Vaseghi G; Rafiee L; Javanmard SH
Curr Gene Ther; 2017; 17(2):147-153. PubMed ID: 28595562
[TBL] [Abstract][Full Text] [Related]
55. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.
Liang C; Guo B; Wu H; Shao N; Li D; Liu J; Dang L; Wang C; Li H; Li S; Lau WK; Cao Y; Yang Z; Lu C; He X; Au DW; Pan X; Zhang BT; Lu C; Zhang H; Yue K; Qian A; Shang P; Xu J; Xiao L; Bian Z; Tan W; Liang Z; He F; Zhang L; Lu A; Zhang G
Nat Med; 2015 Mar; 21(3):288-94. PubMed ID: 25665179
[TBL] [Abstract][Full Text] [Related]
56. Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots.
Citartan M; Kaur H; Presela R; Tang TH
Int J Pharm; 2019 Aug; 567():118483. PubMed ID: 31260780
[TBL] [Abstract][Full Text] [Related]
57. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
58. Nanotechnology for in vivo targeted siRNA delivery.
Dahlman JE; Kauffman KJ; Langer R; Anderson DG
Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
[TBL] [Abstract][Full Text] [Related]
59. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery.
Park S; Jeong EJ; Lee J; Rhim T; Lee SK; Lee KY
Carbohydr Polym; 2013 Jan; 92(1):57-62. PubMed ID: 23218265
[TBL] [Abstract][Full Text] [Related]
60. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics.
Dahlman JE; Kauffman KJ; Xing Y; Shaw TE; Mir FF; Dlott CC; Langer R; Anderson DG; Wang ET
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2060-2065. PubMed ID: 28167778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
